Sensei Biotherapeutics initiated with a Buy at Citi

Citi analyst Samantha Semenkow initiated coverage of Sensei Biotherapeutics with a Buy rating and $6 price target. Sensei is an early-staged biotech developing next-generation, conditionally active immune checkpoint inhibitors for the treatment of cancer, Semenkow tells investors in a research note. The analyst says that while early, targeting VISTA has potential broad applicability across multiple tumor types. Semenkow sees a favorable risk/reward at current share levels.